Abstract: Aqueous dispersions of copolymers of ethylenically unsaturated monomers and silicone resins bearing functional groups which are free radically polymerizable are prepared by forming an aqueous miniemulsion of the silicone resin dissolved in an ethylenically unsaturated monomer, the miniemulsion having a D50 droplet size <350 nm, and polymerizing using a free radical polymerization initiator.

Abstract: Methods of forming a composition for treatment, compositions for treatment, and methods of treatment with the compositions are provided. The methods can include coating a synthetic material substrate with a biologic material. A portion of the biologic material can be acid-swelled.

Abstract: A web material containing one or more active agents and methods for making same are provided.

Abstract: A disinfestation article includes a base, external voids and internal voids formed in the base, pesticidal compound disposed in the external and internal voids. The pesticidal compound disposed in the external void being exposed to a surface of the base. The article may further comprise channels connecting one of the internal voids to one of the external voids. The pesticidal compound contains pesticidal particles selected from pyrethroid family or the like. Also claimed is a method of manufacturing which includes mixing pesticidal particles into a molten polymer material to form a mixture, injecting the mixture into a mold to form a molded part, and cooling the molded part to form said disinfestation article.

Abstract: A production method for a semiconductor epitaxial wafer includes: irradiating a surface of a semiconductor wafer with cluster ions to form a modified layer in a surface portion of the semiconductor wafer, in which the modified layer includes a constituent element of the cluster ions in solid solution. The production method further includes forming an epitaxial layer on the modified layer of the semiconductor wafer. The irradiating is performed such that a portion of the modified layer in a thickness direction becomes an amorphous layer and an average depth of an amorphous layer surface from a semiconductor wafer surface-side of the amorphous layer is at least 20 nm from the surface of the semiconductor wafer.

Abstract: The present invention relates to a composition, textile, and mask for reducing the inhalation of pollutants. The composition includes an aqueous solution of an inorganic iodide compound, a metal phthalocyanine, and a polymeric binder. The inorganic iodide can be cuprous iodide, the metal phthalocyanine can be iron phthalocyanine, and the polymeric binder can be polyvinylpyrrolidone or polyvinyl alcohol. This pollutant-inactivating composition neutralizes pollutants such as nitrogen dioxide, sulfur dioxide, ozone, volatile organic compounds and other unpleasant airborne agents, without requiring elevated temperatures or bulky canisters containing adsorbents. Optionally, a humectant can also be incorporated into the coating solution to retain moisture in the active filter matrix, which enhances the activity of the composition to inactivate oxidizing gases and other toxic constituents of air pollution.

Abstract: A bio control surface (100) comprising a substrate (5) and a first plurality of discrete, spaced-apart particles (1) disposed on the substrate (5) and a second plurality of discrete, spaced-apart particles (6) disposed on the substrate (5), wherein the first (1) and second (6) pluralities of discrete, spaced-apart particles are formed from species having different chemical and/or electrical properties. An intermediate layer (4) may be interposed between the particles (1, 6) and the substrate (5). The bio control surface (100) can be activated by exposure to particular conditions, which cause the first (1) and second (6) pluralities of particles to adopt different potentials (+, ?), such that flow of charge, heat, ions etc. can be used to neutralise or kill bacteria or microorganisms resident on the surface (100).

Abstract: A skin care fabric for medical, pharmaceutical or cosmetic use includes at least 80% by weight of microfibers that are a mixture of polyamide and polyester and have a diameter of less than 50 microns. Each microfiber is split to produce fine fibers closely packed in a parallel structure having a capillary effect and an abrasive effect. The fabric has a surface weight of less than 180 g/m2 and is loaded with medical, pharmaceutical or cosmetic active agents. The skin care fabric includes a warp-knitted fabric having a first surface and a second surface opposite the first surface, which is mechanically roughened and cut to become fluffy and yet short-haired and compact and resulting in a further surface enlargement of the fabric structure and a water absorbency of at least four times the surface weight of the fabric.

Abstract: A chemically modified cellulose/alginate co-spun (seacell) fiber, a wound dressing made therefrom and a preparation method thereof. The seacell fiber is subject to a chemical modification through which a hydrophilic carboxymethyl group is introduced into the cellulose structure making the chemically modified seacell fiber more absorbent. The modified cellulose has a degree of substitution of 0.05-0.5; the seacell fiber has a linear density of 0.5-5 dtex and a fiber length of 5-180 mm. The seacell fiber has hygroscopic and gel-forming properties, while retaining its active ingredient of algae particles.

Abstract: Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.

Abstract: Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The pharmaceutical compositions and combinations also allow for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a muscarinic receptor antagonist and a muscarinic receptor agonist.

Abstract: Devices, systems, and methods for delivery of an active agent from the lens capsule to a posterior segment of the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.

Abstract: The subject matter of the present invention is a sterile liquid composition dedicated to administration into or through the skin and/or the lips, wherein said composition comprises, in a physiologically acceptable medium, at least one photo-crosslinkable compound, wherein said compound comprises at least one activated photo-dimerizable group having at least one activated double bond and selected from photo-dimerizable groups carrying a stilbazolium function of formula (Ia) or (Ib) and wherein the photo-dimerizable groups carry a styrylazolium function of formula (II), the photo-dimerizable group(s) being carried by a partially or totally hydrolysed poly(vinyl acetate) polymer, a polysaccharide or a polyvinyl alcohol.

Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.

Abstract: A nail glue composition contains Beta-methoxyethyl cyanoacrylate, octyl cyanoacrylate, and polymethyl methacrylate. The nail glue composition is substantially odorless and has increased softness.

Abstract: A polylactic acid resin composition of the present invention is constructed by dynamically cross-linking a resin mixture containing a polylactic acid-based resin, trans-polyisoprene, and a cross-linking agent. The resin composition can be used for a wide variety of applications such as automobile molded articles, molded articles for electric products, molded articles for agricultural materials, molded articles for business use, and molded articles for daily use.

Abstract: Immune-polyelectrolyte multilayers (iPEMs) that can be made entirely from immune signal compounds are provided. The iPEMs are formed from first layer of a first immune signal compound, and a second layer of the first immune signal compound or a second immune signal compound disposed on the first layer of the first immune signal compound. The immune signal compounds are peptides, polypeptides, nucleic acids, charged derivatives thereof. Combinations of the immune signal compounds may be in adjacent layers. The first immune signal compound and the second immune signal compound have oppositely charged domains. iPEMs can be formed on or include a substrate, such as a sacrificial substrate, which allows for the formation of a three-dimensional void which can hold various other compounds for use in modulating immune responses. The iPEMs are for use in either stimulating an immune response to one or more antigens, or inducing tolerance to one or more antigens.

Abstract: An electrospinning device 1 includes an electrode 10 having a concave curved surface 11 and a needle-shaped spinning nozzle 20 surrounded by the concave curved surface 11 of the electrode 10. With an electric field applied between the electrode 10 and the nozzle 20, a spinning solution is jetted from the tip of the nozzle 20 to form a nanofiber. The nozzle 20 is located such that the direction in which the nozzle 20 extends passes through or near the center of a circle defined by the open end of the concave curved surface 11 of the electrode 10 and that the tip 20a of the nozzle 20 is positioned in or near the plane including the circle defined by the open end.

Abstract: The present invention provides oral care compositions, and in particular toothpaste compositions comprising a calcium salt abrasive and a novel alginate-based binder and rheology modifier, together with methods of use and manufacture thereof.

Abstract: A self-contained heated wax treatment apparatus can include an outer shell and a rack disposed inside the outer shell. The rack can include a receptacle holder and at least one heater holder. A receptacle can be connected to the rack. A heater can be connected to the heater holder of the rack. Activation of the heater causes heat to flow to the receptacle.

Abstract: A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism.

Abstract: An external-use agent for cleaning and caring ovaries, vagina and vulva, which is produced by medical raw materials consisting of propolis extract, zedoary oil, and mint leaf filtrate is provided. On the basis of different properties of each natural Chinese herbal material, using supercritical CO2 technology, separation and extraction, and low-temperature centrifugation are carried out respectively, and they are processed for preparation in a proportion, and then the membrane separation is performed, so that a spraying agent or a caring product is manufactured. It may be used alone in a female reproductive system for preventing the repeated infection and for achieving vulval bacteriostatic or antibacterial purposes and cleaning and deodorizing the vagina, eliminating vulval pruritus, and refreshing and moisturizing vulva and vagina etc., with good cleaning and caring functions and achieving a significant effect.

Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.

Abstract: The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response.

Abstract: This invention provides a 25-OH Vitamin D3 complex, this complex is made of ?-cyclodextrin and/or its derivatives and 25-Hydroxy Vitamin D3. This invention also relates to a method of manufacturing this complex of ?-cyclodextrin and 25-Hydroxy Vitamin D3, as well as its applications. Due to there being many hydroxy groups at the outside of ?-cyclodextrin and/or its derivatives, the complex increases the solubility of entrapped 25-HO Vitamin D3, thus increasing its bioavailability greatly. In addition, the ring structure of ?-cyclodextrin protects the unstable unsaturated double bonds of 25-HO Vitamin D3, shield it from oxygen and other harmful chemicals and make it much more stable.

Abstract: Methods, compositions, and treatment protocols for treating ischemic wounds and inflammatory conditions in a patient. The treatment protocols comprise or consist of using a modified collagen gel (MCG) to promote healing of ischemic wounds and reduce inflammation at the wound site and in other inflammatory conditions. The modified collagen gel comprises generally a dispersion of collagens in an aqueous matrix comprising water and glycerine, where the amount of Type I collagen is greater than the amount of Type II and Type III collagens in the gel.

Abstract: A system suitable for treating a tissue site may include an interface manifold, an interface sealing member, an absorbent layer, and a storage sealing member. The interface manifold may be positioned in fluid communication at the tissue site. The interface sealing member may be adapted to provide a sealed treatment space relative to the tissue site, and the interface manifold may be positioned in the sealed treatment space. The absorbent layer may be for positioning on an exterior facing side of the interface sealing member. The storage sealing member may be adapted to provide a sealed storage space between the storage sealing member and the exterior facing side of the interface sealing member. The absorbent layer may be positioned in the sealed storage space. Other systems, apparatuses, and methods are disclosed.

Abstract: Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically in the treatment of aged skin, and may include phosphatidylserine, vitamins, and other beneficial anti-aging ingredients.

Abstract: A wound-closing dressing, which is suitable for use as part of a reduced-pressure, wound-treatment system, may include a sealing drape, one or more contracting elements, and a gripping member. The contracting element may be coupled to the sealing drape and is configured to contract when activated and to generate a closing force. A gripping member is coupled to the sealing drape and is configured to transmit the closing force to a patient's epidermis. Other dressings, systems, and methods are also disclosed.

Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.

Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analog are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analog thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analog thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.

Abstract: A method of in vivo monitoring the condition of an internal body repair in which an imageable, non-absorbable repair device having non-absorbable, particulate imaging material substantially uniformly dispersed therein has been surgically inserted, including: in vivo sensing of dimensional deformation of or imaging material concentration changes in said repair device during the post-surgical healing process; comparing the sensed values with a previously developed correlation between said sensed values and the values at which failure occurs of comparable repair devices; wherein said sensed values relative to the repair device's failure values, considered in conjunction with the anticipated time for complete healing of said repair, provides information as to the condition of the repair.

Abstract: A bandage includes a body and an adhesive layer. An attachment portion is defined by exposing the adhesive layer. The bandage includes a first removable dressing component having a predetermined length and width carried by the adhesive layer disposed over the central axis of the body. A second removable dressing component having a predetermined length and width is also carried by the adhesive layer. The respective widths of the first and second removable dressing components being less than the width of the body enabling a side edge attachment portion to be defined proximate the side edges of the body and wherein the removal of the first removable dressing component exposes the adhesive layer defining an end attachment portion of the bandage.

Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.

Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.

Abstract: The present invention provides a process or preparing an extracellular matrix composition which comprises: (a) mixing an aqueous solution of fibrinogen with a coagulating agent and a bulking agent and a foaming agent; (b) causing the mixture to foam and coagulate; (c) incubating the mixture obtained in step (b) with a cross-linking agent; and (d) washing the cross-linked composition obtained in step (c) to remove the cross-linking agent. Wherein the foaming agent consists of or comprises one or more surfactant agent(s) from the class of sugar-surfactants. The invention also relates to the formulation mixture as such, and to the products of the process.

Abstract: Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.

Abstract: A multi-phase silicone acrylic hybrid visco-elastic composition prepared by polymerizing an ethylenically unsaturated monomer and a silicon-containing pressure sensitive adhesive composition comprising acrylate or methacrylate functionality in a first solvent in the presence of an initiator, removing the first solvent, and adding a second solvent to form the multi-phase silicone acrylic hybrid visco-elastic composition. Alternatively, a multi-phase silicone acrylic hybrid visco-elastic composition prepared by polymerizing an ethylenically unsaturated monomer and a silicon-containing pressure sensitive adhesive composition comprising acrylate or methacrylate functionality in a first solvent in the presence of an initiator, adding a processing solvent having a higher boiling point than the first solvent, applying heat to selectively remove a majority of the first solvent, removing the processing solvent, and adding a second solvent to form the multi-phase silicone acrylic hybrid visco-elastic composition.

Abstract: To provide tissue paper with an excellent “moist texture” and high “smooth texture.” 2-ply tissue paper is characterized by the basis weight per ply being 15 to 18 g/m2, the 2-ply paper thickness being 135 to 160 ?m, and containing 2.9 g/m2 or more and 8.0 g/m2 or less of chemical agent which contains glycerin and 1,3-propanediol in a total amount of 83.7 mass % or more, wherein the mass ratio of glycerin and 1,3-propanediol is 1:0.04 or more and 1:5.58 or less.

Abstract: Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

Abstract: An improved abdominal hernia repair system is presented comprised of a silicone layer backed up with a knitted or woven polypropylene fabric layer, the silicone layer possessing a regular pattern of slits that permit equilibration of fluid pressure across the device. A variety of therapeutic substances can be applied to the hernia repair device to promote healing, including aloe and other medicinal preparations. A layer of water soluble or water insoluble anti-scar compound is also present, the preferred compound being Salinomycin. An improved inguinal hernia repair system is presented that is identical to the above except it does not contain the hydrophobic silicone component.

Abstract: The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

Abstract: The present invention relates to a method for coating an inert or naturally occurring material with a silk polypeptide. It further relates to a coated inert or naturally occurring material obtainable by said method and to uses thereof. It also relates to products comprising said coated material.

Abstract: A high-recoverability resin particles having a mean particle size of 1 to 100 ?m containing a cross-linked (meth)acrylic acid ester-based resin, wherein the high-recoverability resin particles have a recovery rate of 22% or greater, and a 30% compression strength of 1.5 to 5.0 kgf/mm2.

Abstract: The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 ?g of LL-37 applied per cm2 of wound area, and/or below about 26.7 ?g of LL-37 applied per cm2 of wound area, per day of treatment.

Abstract: Some embodiments of the present disclosure relate to a wound packing material, suitable for use in negative pressure wound therapy, comprising a body of a porous material, the body comprising frangible regions defining a plurality of portions, the frangible regions allowing the portions to be selectively removed from the body. The wound packing material can be shaped to partially or fully surround a secondary wound packing member, such as a stabilizing structure. Some embodiments further relate to methods of manufacturing the wound packing material, and to methods of its use.

Abstract: Post-scar formation reduction apparatus comprises a biocompatible scar interface layer, a compressible pressure chamber overlying the scar interface layer, and an at least substantially uniformly compressible pressure element in the pressure chamber which extends over the scar interface layer. The pressure element has a bulk modulus enabling a predetermined uniform or substantially uniform compression of the pressure element in at least a direction perpendicular or substantially perpendicular to the scar interface layer on application of a specific pressure. Evacuator is also provided which at least partially evacuates the pressure chamber, whereby the pressure element is uniformly or substantially uniformly compressed in the direction of the scar interface layer and the pressure chamber positively urges the compressed pressure element towards the scar interface layer.